PTGS1 and ulcer disease: These adverse effects are largely attributed to the inhibition of cyclooxygenase-1 (COX-1), which not only disrupts the protective lining of the stomach but also suppresses platelet aggregation, thereby increasing the risk of bleeding and ulcer formation [8,9].